Johnson Fistel has launched an investigation into

SAN DIEGO, July 22, 2024 (GLOBE NEWSWIRE) — Shareholder rights law firm Johnson Fistel, LLP is investigating whether Endava plc (NYSE: DAVA) (the “Company”) or any of its officers or others violated securities laws by misrepresenting or failing to timely disclose material, adverse information to investors. The investigation is focused on investors’ losses and whether they can be recovered under the federal securities laws.

What happens once I have purchased? Endava Securities? If you have purchased securities and suffered significant losses, join our investigation now:

Click here to take part in the survey

For more information contact Jim Baker at [email protected] or (619) 814-4471

There are no costs or obligations to you.

What if I have relevant non-public information? Persons with nonpublic information about the Company should consider assisting with our investigation or utilizing the SEC Whistleblower Program. Under the SEC Program, whistleblowers who provide original information may, under certain circumstances, receive rewards of up to thirty percent of any successful SEC recovery. For more information, contact Jim Baker at (619) 814-4471 or [email protected].

About Johnson Fistel, LLP:
Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia and Colorado. The firm represents individual and institutional investors in shareholder class action lawsuits involving derivatives and securities. For more information about the firm and its attorneys, visit http://www.johnsonfistel.com.

Lawyer advertising.
Past results are no guarantee of future results.
Services can be provided by attorneys in any of our offices.

Johnson Fistel, LLP has paid for the distribution of this advertisement and Frank J. Johnson is the attorney responsible for its content.

Contact:
Johnson Fistula, LLP
501 W. Broadway, Suite 800, San Diego, CA 92101
James Baker, Investor Relations or Frank J. Johnson, Esq., (619) 814-4471
[email protected] or [email protected]